Sorafenib and entecavir: The dioscuri of treatment for advanced hepatocellular carcinoma?

被引：4

作者：

D'Angelo, Salvatore ^{[1
]}

Secondulfo, Mario ^{[1
]}

De Cristofano, Raffaele ^{[1
]}

Sorrentino, Paolo ^{[1
]}

机构：

[1] SG Moscati Hosp, Liver Unit, I-83100 Avellino, Italy

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2013年 / 19卷 / 14期

关键词：

Entecavir; Hepatocellular carcinoma; Hepatitis B virus; Liver function; Sorafenib; HEPATITIS-B-VIRUS; CIRRHOSIS; EFFICACY; INFECTION; THERAPY; CANCER;

D O I：

10.3748/wjg.v19.i14.2141

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Hepatitis B virus (HBV) is responsible for 50%-80% of cases of hepatocellular carcinoma (HCC) worldwide. Entecavir (ET) is a potent inhibitor of chronic HBV-DNA polymerase, inhibiting both the priming and elongation steps of viral DNA replication. Sorafenib (SO) has proven efficacy in prolonging survival in patients with advanced HCC. In this frontier report we discuss a possible way to optimize treatment outcomes in patients with HBV and HCC by treatment with ET and SO, on the basis of our practice and published evidence from the literature. (C) 2013 Baishideng. All rights reserved.

引用

页码：2141 / 2143

页数：3

共 50 条

[21] Oral sorafenib for advanced hepatocellular carcinoma
Nature Clinical Practice Oncology, 2006, 3 (12): : 648 - 649
[22] Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
Sanoff, Hanna K.
Chang, YunKyung
Lund, Jennifer L.
O'Neil, Bert H.
Dusetzina, Stacie B.
ONCOLOGIST, 2016, 21 (09): : 1113 - 1120
[23] Sorafenib for the treatment of hepatocellular carcinoma
Woerns, Marcus Alexander
Galle, Peter Robert
HEPATIC ONCOLOGY, 2014, 1 (02) : 189 - 204
[24] S-1 plus sorafenib for the treatment of advanced hepatocellular carcinoma
Huang, Wukui
You, Lina
Liu, Dengyao
Yang, Shufa
Liu, Mo
Wang, Hailin
Wang, Pingju
Baikere, Pahaerding
Gu, Peng
Abulikemu, Abulajiang
Yuan, Shaoha
Fan, Xiwen
JOURNAL OF BUON, 2016, 21 (06): : 1388 - 1393
[25] Expression of Keratin 19 in advanced hepatocellular carcinoma and resistance to sorafenib treatment
Wen, X.
Xu, X.
TRANSPLANTATION, 2019, 103 (08) : 62 - 62
[26] SORAFENIB TREATMENT FOR HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH ADVANCED LIVER DISEASE
Alves, Rogerio C.
Alves, Daniele E.
Guz, Betty
Viana, Monica V.
Harriz, Michelle C.
Matos, Carla A.
Terrabuio, Deborah
Chagas, Aline
Moutinho, Renata D.
Taddeo, Eliane F.
Duarte, Kelly C.
Oliveira, George P.
Ribeirol, Juliana M.
Kondo, Mario
Gampel, Otavio
Poletti, Paula
HEPATOLOGY, 2010, 52 (04) : 1193A - 1193A
[27] Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma
Takada, Hitomi
Kurosaki, Masayuki
Nakanishi, Hiroyuki
Takahashi, Yuka
Itakura, Jun
Tsuchiya, Kaoru
Yasui, Yutaka
Tamaki, Nobuharu
Takaura, Kenta
Komiyama, Yasuyuki
Higuchi, Mayu
Kubota, Youhei
Wang, Wann
Okada, Mao
Enomoto, Nobuyuki
Izumi, Namiki
PLOS ONE, 2018, 13 (06):
[28] Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India
Gupta, Nidhi
Verma, Rohan K.
Prinja, Shankar
Dhiman, Radha K.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 9 (04) : 468 - 475
[29] Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma
Takeyama, Hideaki
Beppu, Toru
Higashi, Takaaki
Kaida, Takayoshi
Arima, Kota
Taki, Katsunobu
Imai, Katsunori
Nitta, Hidetoshi
Hayashi, Hiromitsu
Nakagawa, Shigeki
Okabe, Hirohisa
Hashimoto, Daisuke
Chikamoto, Akira
Ishiko, Takatoshi
Tanaka, Motohiko
Sasaki, Yutaka
Baba, Hideo
SURGERY TODAY, 2018, 48 (04) : 431 - 438
[30] Diarrhea Is a Positive Outcome Predictor for Sorafenib Treatment of Advanced Hepatocellular Carcinoma
Koschny, Ronald
Gotthardt, Daniel
Koehler, Christiane
Jaeger, Dirk
Stremmel, Wolfgang
Ganten, Tom M.
ONCOLOGY, 2013, 84 (01) : 6 - 13

← 1 2 3 4 5 →